-
13 October 2025
-
13 October 2025
ESMO 2025: new data reinforces breadth and depth of Ipsen’s growing oncology pipeline and portfolio
PARIS, FRANCE, 13 October 2025 – Ipsen announced today data to be presented at the upcoming European Society of Medical Oncology (ESMO) Symposium on 17-21 October 2025 for rare cancers and complex tumors, offering opportunities to change the course of di...
-
31 May 2025
-
31 May 2025
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
PARIS, France, 31 May 2025 – Late-breaking (LBA4175) post-hoc analysis data from the Phase III NAPOLI 3 study were presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These results found a median overall survival (mOS...
-
13 October 2025
-
13 October 2025
ESMO 2025 : les données d’Ipsen enrichissent et élargissent son portefeuille de produits en R&D et commercialisés en Oncologie
PARIS, FRANCE, le 13 octobre 2025– Ipsen annonce aujourd’hui la communication de nouvelles données lors du prochain congrès de l’European Society of Medical Oncology (ESMO) qui se tiendra du 17 au 21 octobre 2025 et mettra en lumière les cancers r...
-
13 February 2024
-
13 February 2024
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
PARIS, FRANCE, 13 February 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorour...
-
24 July 2025
-
24 July 2025
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine t...
-
20 June 2025
-
20 June 2025
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult pat...
-
31 May 2025
-
31 May 2025
Une analyse « Late Breaking » démontre les caractéristiques associées à la survie globale à long terme des patients avec un adénocarcinome pancréatique métastatique traités par Onivyde®
PARIS, France, le 31 mai 2025 – Les données d’une analyse post-hoc « Late Breaking » (LBA4175) de l’étude de Phase III NAPOLI 3 ont été présentées aujourd’hui lors du congrès 2025 de l’American Society of Clinical Oncology (ASCO). Ces r...
-
13 February 2024
-
13 February 2024
Ipsen reçoit l’approbation de la FDA pour le schéma thérapeutique incluant Onivyde®, un potentiel nouveau traitement de référence en première ligne dans l’adénocarcinome du pancréas métastatique
PARIS, FRANCE, le 13 février 2024 - Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd’hui que les autorités américaines (Food and Drug Administration, FDA) ont approuvé l’indication supplémentaire d'Onivyde® (irinotécan liposomal en injection...
-
02 July 2024
-
02 July 2024
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
PARIS, FRANCE, 2 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today confirmation of an expanded collaboration and license agreement with Exelixis, Inc. for the development of Cabometyx® (cabozantinib) in advanced pancreatic neuroendocrine tumor...